{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:38:50Z","timestamp":1778607530532,"version":"3.51.4"},"reference-count":16,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"Importance<\/jats:title>Retrospective case series have identified having cancer and receiving treatment for cancer as risk factors for inferior COVID-19 outcomes.<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine risk factors for hospitalization and death in patients with cancer with COVID-19 infection.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>The National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS) is a prospective longitudinal natural history cohort study examining the impact of COVID-19 on patients with cancer. Adults were eligible within 14 days of an initial positive SARS-CoV-2 test result if they were receiving active treatment for cancer or had prior stem cell\/bone marrow transplant or CAR T-cell treatment. The statistical analysis took place between September 2024 and April 2025.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary objective of the study was to determine patient factors, therapy types, and cancer types associated with COVID-19 severity, defined as hospitalization for or death from COVID-19 within 30 and 90 days after the first positive SARS-CoV-2 test result. Multivariable regressions were performed for COVID-19\u2013specific hospitalization and mortality (proportional hazard and cause-specific hazard models).<\/jats:p><\/jats:sec>Results<\/jats:title>Of 1572 eligible adult patients (median [range] age, 60 [18-93] years; 840 female [53.4%]), 1066 (67.8%) had a solid tumor, with 683 (64.0%) having metastatic disease; breast (252 [23.6%]) and lung cancer (148 [13.9%]) were most common. At enrollment, 1013 patients (64.4%) were unvaccinated for SARS-CoV-2. COVID-19\u2013related mortality at 90 days was 3.0% and did not increase at subsequent time points. The cumulative incidence of COVID-19\u2013specific death in the first 90 days was highest in patients with lymphoma, intermediate in patients with acute leukemia and lung cancer, and lowest in patients with other solid tumors and other hematologic cancers. In multivariable analysis, receipt of chemotherapy (hazard ratio [HR], 1.97; 95% CI, 1.52-2.54) and baseline history of stroke, atrial fibrillation, or pulmonary embolism (HR, 1.78; 95% CI, 1.33-2.38) were associated with a higher risk of hospitalization. Vaccination prior to SARS-CoV-2 infection was associated with a lower risk of hospitalization (HR, 0.52; 95% CI, 0.38-0.70). Over 2 years of follow-up, there were 1739 cancer treatment disruptions, of which 881 (50.7%) were attributed to COVID-19, with most disruptions occurring within the first 30 days.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The results of this prospective cohort study showed that COVID-19 had a significant impact on patients with cancer, including hospitalization, treatment disruptions, and death.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2025.2010","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T15:00:37Z","timestamp":1752764437000},"page":"990","source":"Crossref","is-referenced-by-count":6,"title":["Risk Factors for COVID-19\u2013Related Hospitalization and Death in Patients With Cancer"],"prefix":"10.1001","volume":"11","author":[{"given":"Brian I.","family":"Rini","sequence":"first","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center, Nashville, Tennessee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana F.","family":"Best","sequence":"additional","affiliation":[{"name":"Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mel D.","family":"Bowman","sequence":"additional","affiliation":[{"name":"The Emmes Company LLC, Rockville, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace E.","family":"Mishkin","sequence":"additional","affiliation":[{"name":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea M.","family":"Denicoff","sequence":"additional","affiliation":[{"name":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry V.","family":"Rubinstein","sequence":"additional","affiliation":[{"name":"Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyndsay","family":"Harris","sequence":"additional","affiliation":[{"name":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann M.","family":"Geiger","sequence":"additional","affiliation":[{"name":"National Cancer Institute Center for Strategic Scientific Initiatives, Rockville, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas M.","family":"Mark","sequence":"additional","affiliation":[{"name":"Swedish Medical Center, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven A.","family":"Pergam","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy L.","family":"Warner","sequence":"additional","affiliation":[{"name":"Warren Alpert Medical School of Brown University, Providence, Rhode Island"},{"name":"Department of Biostatistics, School of Public Health, Brown University, Providence, Rhode Island"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alok A.","family":"Khorana","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Cleveland, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sacha","family":"Gnjatic","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina W.F.","family":"Yen","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milwaukee"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darla K.","family":"Liles","sequence":"additional","affiliation":[{"name":"East Carolina University Brody School of Medicine, Greenville, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine M.","family":"Bestvina","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil J.","family":"Shah","sequence":"additional","affiliation":[{"name":"Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline T.","family":"Norrell","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, New Brunswick"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn L.","family":"Hershman","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Holter-Chakrabarty","sequence":"additional","affiliation":[{"name":"University of Oklahoma College of Medicine, Oklahoma City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew S.","family":"Poklepovic","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University Massey Cancer Center, Richmond"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Chanock","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hari","family":"Sankaran","sequence":"additional","affiliation":[{"name":"Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larissa A.","family":"Korde","sequence":"additional","affiliation":[{"name":"Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"1","key":"coi250032r1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12016-022-08921-5","article-title":"Risk and protective factors for COVID-19 morbidity, severity, and mortality.","volume":"64","author":"Zhang","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"coi250032r2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.10880","article-title":"Differences in outcomes and factors associated with mortality among patients with SARS-CoV-2 infection and cancer compared with those without cancer: a systematic review and meta-analysis.","volume":"5","author":"Khoury","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"6","key":"coi250032r3","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.annonc.2021.02.024","article-title":"Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.","volume":"32","author":"Grivas","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"coi250032r4","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.jtho.2021.12.015","article-title":"A definitive prognostication system for patients with thoracic malignancies diagnosed with coronavirus disease 2019: an update from the TERAVOLT registry.","volume":"17","author":"Whisenant","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"26","key":"coi250032r5","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1056\/NEJMc2031670","article-title":"Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer.","volume":"383","author":"Aydillo","year":"2020","journal-title":"N Engl J Med"},{"key":"coi250032r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104208","article-title":"Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: results from the IMPACC study.","volume":"83","author":"Ozonoff","year":"2022","journal-title":"EBioMedicine"},{"issue":"1","key":"coi250032r8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1541-0420.2010.01420.x","article-title":"Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring.","volume":"67","author":"Geskus","year":"2011","journal-title":"Biometrics"},{"issue":"2","key":"coi250032r9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/biomet\/76.2.297","article-title":"Regression and time series model selection in small samples.","volume":"76","author":"Hurvich","year":"1989","journal-title":"Biometrika"},{"issue":"26","key":"coi250032r10","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1056\/NEJMc2031670","article-title":"Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer.","volume":"383","author":"Aydillo","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"coi250032r12","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/jnci\/djad015","article-title":"COVID-19 severity by vaccination status in the NCI COVID-19 and Cancer Patients Study (NCCAPS).","volume":"115","author":"Best","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"coi250032r13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0130","article-title":"Mortality among adults with cancer undergoing chemotherapy or immunotherapy and infected with COVID-19.","volume":"5","author":"V\u00e1rnai","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2","key":"coi250032r14","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/bjh.19562","article-title":"Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.","volume":"205","author":"Lim","year":"2024","journal-title":"Br J Haematol"},{"issue":"7","key":"coi250032r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2024.102473","article-title":"Immune response against the SARS-CoV-2 spike protein in cancer patients after COVID-19 vaccination during the Omicron wave: a prospective study.","volume":"17","author":"Mu\u00f1oz-G\u00f3mez","year":"2024","journal-title":"J Infect Public Health"},{"key":"coi250032r16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2147\/CLEP.S463160","article-title":"The impact of the COVID-19 pandemic on incidence and short-term survival for common solid tumours in the United Kingdom: a cohort analysis.","volume":"16","author":"Barclay","year":"2024","journal-title":"Clin Epidemiol"},{"key":"coi250032r6","unstructured":"US Food and Drug Administration. Policy for coronavirus disease\u20142019 tests: guidance for developers and food and drug administration staff. Updated January 2023. Accessed June 10, 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/policy-coronavirus-disease-2019-tests-revised"},{"key":"coi250032r11","unstructured":"US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19. December 22, 2021. Accessed June 10, 2025. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2836492\/jamaoncology_rini_2025_oi_250032_1757953489.21838.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T15:19:30Z","timestamp":1758208770000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2836492"}},"subtitle":["The National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS)"],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.2010","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}